the present invention is obtained by introducing a glycerate moiety between a vancomycin derivative and a liposoluble modification group and has reduced liposolubility and improved water solubility thereby reducing a side effect in the cardiovascular aspect application_number US 201414912573 A description the compound of formula 1 of the present invention or a clinically acceptable salt thereof is intended to be used for treatment of gram positive bacteria or vancomycin resistant bacteria infection cases to verify the activity a group of the compounds of the present invention were preferably subjected to in vitro activity assay table 1 in vitro activity assay was performed according to microbiological identification of antibiotics appendix xia volume ii chinese pharmacopoeia 2010 vancomycin sensitive staphylococcus aureus strains newman and mu 50 were selected as the test strains and trypticase soy broth was selected as the culture medium the assay for minimum inhibitory concentration mic was performed as follows the compound to be tested was dissolved in n n dimethylformamide to prepare a stock solution at 1 28 mg ml the stock solution was diluted with the culture medium to a initial concentration of 1 28 u03bcg ml which was subsequently half diluted to prepare test solutions at 64 u03bcg ml 0 125 u03bcg ml and the assay was performed according to cup plate.